Article

Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptides

2025-04-02

Abstract excerpt

KRAS is a proto-oncogene that contains activating mutations in up to 30% of tumors. Many conventional therapies inhibit both cancerous and normal cells, which may cause toxicity. Thus, programmable mutant-selective targeted inhibitors are needed. Peptide nucleic acids (PNAs) incorporate base sequences analogous to DNA, with modified peptide backbones instead of ribose-phosphate backbones, allowing PNAs to hybridiz...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1327c9e8-42df-5531-9122-1bbf98a53500
DOI: 10.1101/2025.03.28.645837

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesDOI 10.1101/2025.03.28.645837Read

Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.Semantic proximity Read

Targeting cancer with small-molecule pan-KRAS degraders.Semantic proximity Read

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read

Precision medicine by designer interference peptides: applications in oncology and molecular therapeuticsSemantic proximity Read

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signalingSemantic proximity Read

EFTX-G12V: a novel KRASG12V-selective RNAi therapeutic.Semantic proximity Read

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read

A first-in-class EGFR-directed KRAS G12V selective inhibitor.Semantic proximity Read

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read

Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.Semantic proximity Read

A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS MutantsSemantic proximity Read